Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2004 Jul;75(7):951–957. doi: 10.1136/jnnp.2003.034702

Botulinum toxin in clinical practice

J Jankovic 1
PMCID: PMC1739107  PMID: 15201348

Abstract

Botulinum toxin, the most potent biological toxin, has become a powerful therapeutic tool for a growing number of clinical applications. This review draws attention to new findings about the mechanism of action of botulinum toxin and briefly reviews some of its most frequent uses, focusing on evidence based data. Double blind, placebo controlled studies, as well as open label clinical trials, provide evidence that, when appropriate targets and doses are selected, botulinum toxin temporarily ameliorates disorders associated with excessive muscle contraction or autonomic dysfunction. When injected not more often than every three months, the risk of blocking antibodies is slight. Long term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for an increasing number of off-label indications.

Full Text

The Full Text of this article is available as a PDF (103.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abstracts of the 8th International Congress of Parkinson's Disease and Movement Disorders. June 14-17, 2004. Rome, Italy. Mov Disord. 2004;19 (Suppl 9):S1–S491. doi: 10.1002/mds.20167. [DOI] [PubMed] [Google Scholar]
  2. Adler C. H., Zimmerman R. S., Lyons M. K., Simeone F., Brin M. F. Perioperative use of botulinum toxin for movement disorder-induced cervical spine disease. Mov Disord. 1996 Jan;11(1):79–81. doi: 10.1002/mds.870110114. [DOI] [PubMed] [Google Scholar]
  3. Adler M., Keller J. E., Sheridan R. E., Deshpande S. S. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon. 2001 Feb-Mar;39(2-3):233–243. doi: 10.1016/s0041-0101(00)00120-3. [DOI] [PubMed] [Google Scholar]
  4. Albanese A., Maria G., Bentivoglio A. R., Brisinda G., Cassetta E., Tonali P. Severe constipation in Parkinson's disease relieved by botulinum toxin. Mov Disord. 1997 Sep;12(5):764–766. doi: 10.1002/mds.870120524. [DOI] [PubMed] [Google Scholar]
  5. Armstrong M. W., Mountain R. E., Murray J. A. Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy. Clin Otolaryngol Allied Sci. 1996 Feb;21(1):15–20. doi: 10.1111/j.1365-2273.1996.tb01018.x. [DOI] [PubMed] [Google Scholar]
  6. Arnon S. S., Schechter R., Inglesby T. V., Henderson D. A., Bartlett J. G., Ascher M. S., Eitzen E., Fine A. D., Hauer J., Layton M. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001 Feb 28;285(8):1059–1070. doi: 10.1001/jama.285.8.1059. [DOI] [PubMed] [Google Scholar]
  7. Ashkenazi Avi, Silberstein Stephen D. Botulinum toxin and other new approaches to migraine therapy. Annu Rev Med. 2004;55:505–518. doi: 10.1146/annurev.med.55.091902.104440. [DOI] [PubMed] [Google Scholar]
  8. Atassi M. Zouhair. Basic immunological aspects of botulinum toxin therapy. Mov Disord. 2004 Mar;19 (Suppl 8):S68–S84. doi: 10.1002/mds.20020. [DOI] [PubMed] [Google Scholar]
  9. Baker R., Jasinski M., Maciag-Tymecka I., Michalowska-Mrozek J., Bonikowski M., Carr L., MacLean J., Lin J. P., Lynch B., Theologis T. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol. 2002 Oct;44(10):666–675. doi: 10.1017/s0012162201002730. [DOI] [PubMed] [Google Scholar]
  10. Bhakta B. B., Cozens J. A., Chamberlain M. A., Bamford J. M. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):217–221. doi: 10.1136/jnnp.69.2.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Blersch Wendelin, Schulte-Mattler Wilhelm J., Przywara Saskia, May Arne, Bigalke Hans, Wohlfarth Kai. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci. 2002 Dec 15;205(1):59–63. doi: 10.1016/s0022-510x(02)00313-1. [DOI] [PubMed] [Google Scholar]
  12. Boroojerdi B., Ferbert A., Schwarz M., Herath H., Noth J. Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry. 1998 Jul;65(1):111–114. doi: 10.1136/jnnp.65.1.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Boyd R. N., Morris M. E., Graham H. K. Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol. 2001 Nov;8 (Suppl 5):150–166. doi: 10.1046/j.1468-1331.2001.00048.x. [DOI] [PubMed] [Google Scholar]
  14. Brashear A., Lew M. F., Dykstra D. D., Comella C. L., Factor S. A., Rodnitzky R. L., Trosch R., Singer C., Brin M. F., Murray J. J. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999 Oct 22;53(7):1439–1446. doi: 10.1212/wnl.53.7.1439. [DOI] [PubMed] [Google Scholar]
  15. Brashear Allison, Gordon Mark F., Elovic Elie, Kassicieh V. Daniel, Marciniak Christina, Do Mai, Lee Chia-Ho, Jenkins Stephen, Turkel Catherine, Botox Post-Stroke Spasticity Study Group Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002 Aug 8;347(6):395–400. doi: 10.1056/NEJMoa011892. [DOI] [PubMed] [Google Scholar]
  16. Brin M. F., Lew M. F., Adler C. H., Comella C. L., Factor S. A., Jankovic J., O'Brien C., Murray J. J., Wallace J. D., Willmer-Hulme A. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431–1438. doi: 10.1212/wnl.53.7.1431. [DOI] [PubMed] [Google Scholar]
  17. Brin M. F., Lyons K. E., Doucette J., Adler C. H., Caviness J. N., Comella C. L., Dubinsky R. M., Friedman J. H., Manyam B. V., Matsumoto J. Y. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12;56(11):1523–1528. doi: 10.1212/wnl.56.11.1523. [DOI] [PubMed] [Google Scholar]
  18. Brin M. F., Stewart C., Blitzer A., Diamond B. Laryngeal botulinum toxin injections for disabling stuttering in adults. Neurology. 1994 Dec;44(12):2262–2266. doi: 10.1212/wnl.44.12.2262. [DOI] [PubMed] [Google Scholar]
  19. Brin M. F., Vapnek J. M. Treatment of vaginismus with botulinum toxin injections. Lancet. 1997 Jan 25;349(9047):252–253. doi: 10.1016/S0140-6736(05)64862-3. [DOI] [PubMed] [Google Scholar]
  20. Brisinda G., Maria G., Bentivoglio A. R., Cassetta E., Gui D., Albanese A. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med. 1999 Jul 8;341(2):65–69. doi: 10.1056/NEJM199907083410201. [DOI] [PubMed] [Google Scholar]
  21. Burbaud P., Wiart L., Dubos J. L., Gaujard E., Debelleix X., Joseph P. A., Mazaux J. M., Bioulac B., Barat M., Lagueny A. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):265–269. doi: 10.1136/jnnp.61.3.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Bushara Magda Amin, Bushara Khalaf. Botulinum toxin, sweating, and body odor. N Engl J Med. 2002 Aug 22;347(8):620–621. doi: 10.1056/NEJM200208223470819. [DOI] [PubMed] [Google Scholar]
  23. Byrnes M. L., Thickbroom G. W., Wilson S. A., Sacco P., Shipman J. M., Stell R., Mastaglia F. L. The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection. Brain. 1998 May;121(Pt 5):977–988. doi: 10.1093/brain/121.5.977. [DOI] [PubMed] [Google Scholar]
  24. Chen R., Karp B. I., Hallett M. Botulinum toxin type F for treatment of dystonia: long-term experience. Neurology. 1998 Nov;51(5):1494–1496. doi: 10.1212/wnl.51.5.1494. [DOI] [PubMed] [Google Scholar]
  25. Cho J. W., Chu K., Jeon B. S. Case of essential palatal tremor: atypical features and remarkable benefit from botulinum toxin injection. Mov Disord. 2001 Jul;16(4):779–782. doi: 10.1002/mds.1132. [DOI] [PubMed] [Google Scholar]
  26. Cordivari C., Misra V. P., Catania S., Lees A. J. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 2001 Sep;16(5):907–913. doi: 10.1002/mds.1186. [DOI] [PubMed] [Google Scholar]
  27. Courey M. S., Garrett C. G., Billante C. R., Stone R. E., Portell M. D., Smith T. L., Netterville J. L. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Ann Otol Rhinol Laryngol. 2000 Sep;109(9):819–822. doi: 10.1177/000348940010900906. [DOI] [PubMed] [Google Scholar]
  28. Davis D., Jabbari B. Significant improvement of stiff-person syndrome after paraspinal injection of botulinum toxin A. Mov Disord. 1993 Jul;8(3):371–373. doi: 10.1002/mds.870080323. [DOI] [PubMed] [Google Scholar]
  29. Defazio Giovanni, Abbruzzese Giovanni, Girlanda Paolo, Vacca Laura, Currà Antonio, De Salvia Roberto, Marchese Roberta, Raineri Roberto, Roselli Francesco, Livrea Paolo. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol. 2002 Mar;59(3):418–420. doi: 10.1001/archneur.59.3.418. [DOI] [PubMed] [Google Scholar]
  30. Devriese P. P. On the discovery of Clostridium botulinum. J Hist Neurosci. 1999 Apr;8(1):43–50. doi: 10.1076/jhin.8.1.43.1774. [DOI] [PubMed] [Google Scholar]
  31. Dolimbek Behzod Z., Jankovic Joseph, Atassi M. Zouhair. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002 Aug-Nov;31(3-4):247–262. doi: 10.1081/imm-120016244. [DOI] [PubMed] [Google Scholar]
  32. Eaker E. Y., Gordon J. M., Vogel S. B. Untoward effects of esophageal botulinum toxin injection in the treatment of achalasia. Dig Dis Sci. 1997 Apr;42(4):724–727. doi: 10.1023/a:1018843526027. [DOI] [PubMed] [Google Scholar]
  33. Eisenschenk S., Gilmore R. L., Uthman B., Valenstein E., Gonzalez R. Botulinum toxin-induced paralysis of frontotemporal muscles improves seizure focus localization. Neurology. 2002 Jan 22;58(2):246–249. doi: 10.1212/wnl.58.2.246. [DOI] [PubMed] [Google Scholar]
  34. Eleopra Roberto, Tugnoli Valeria, Quatrale Rocco, Rossetto Ornella, Montecucco Cesare. Different types of botulinum toxin in humans. Mov Disord. 2004 Mar;19 (Suppl 8):S53–S59. doi: 10.1002/mds.20010. [DOI] [PubMed] [Google Scholar]
  35. Erbguth F. J., Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology. 1999 Nov 10;53(8):1850–1853. doi: 10.1212/wnl.53.8.1850. [DOI] [PubMed] [Google Scholar]
  36. Evers S., Rahmann A., Vollmer-Haase J., Husstedt I-W. Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria. Cephalalgia. 2002 Nov;22(9):699–710. doi: 10.1046/j.1468-2982.2002.00390.x. [DOI] [PubMed] [Google Scholar]
  37. Fon E. A., Edwards R. H. Molecular mechanisms of neurotransmitter release. Muscle Nerve. 2001 May;24(5):581–601. doi: 10.1002/mus.1044. [DOI] [PubMed] [Google Scholar]
  38. Foran Patrick G., Mohammed Nadiem, Lisk Godfrey O., Nagwaney Sharuna, Lawrence Gary W., Johnson Eric, Smith Leonard, Aoki K. Roger, Dolly J. Oliver. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 2002 Oct 14;278(2):1363–1371. doi: 10.1074/jbc.M209821200. [DOI] [PubMed] [Google Scholar]
  39. Foster L., Clapp L., Erickson M., Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001 May 22;56(10):1290–1293. doi: 10.1212/wnl.56.10.1290. [DOI] [PubMed] [Google Scholar]
  40. Frampton James E., Easthope Stephanie E. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol. 2003;4(10):709–725. doi: 10.2165/00128071-200304100-00005. [DOI] [PubMed] [Google Scholar]
  41. Giess R., Naumann M., Werner E., Riemann R., Beck M., Puls I., Reiners C., Toyka K. V. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2000 Jul;69(1):121–123. doi: 10.1136/jnnp.69.1.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Giladi N., Gurevich T., Shabtai H., Paleacu D., Simon E. S. The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study. J Neurol. 2001 Jul;248(7):572–576. doi: 10.1007/s004150170134. [DOI] [PubMed] [Google Scholar]
  43. Graham H. K., Aoki K. R., Autti-Rämö I., Boyd R. N., Delgado M. R., Gaebler-Spira D. J., Gormley M. E., Guyer B. M., Heinen F., Holton A. F. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000 Feb;11(1):67–79. doi: 10.1016/s0966-6362(99)00054-5. [DOI] [PubMed] [Google Scholar]
  44. Grazko M. A., Polo K. B., Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology. 1995 Apr;45(4):712–717. doi: 10.1212/wnl.45.4.712. [DOI] [PubMed] [Google Scholar]
  45. Gudex C. M., Hawthorne M. R., Butler A. G., Duffey P. Effect of dystonia and botulinum toxin treatment on health-related quality of life. Mov Disord. 1998 Nov;13(6):941–946. doi: 10.1002/mds.870130613. [DOI] [PubMed] [Google Scholar]
  46. Hanna P. A., Jankovic J., Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999 May;66(5):612–616. doi: 10.1136/jnnp.66.5.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Heckmann M., Ceballos-Baumann A. O., Plewig G., Hyperhidrosis Study Group Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med. 2001 Feb 15;344(7):488–493. doi: 10.1056/NEJM200102153440704. [DOI] [PubMed] [Google Scholar]
  48. Hsiung G-Y R., Das S. K., Ranawaya R., Lafontaine A-L, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord. 2002 Nov;17(6):1288–1293. doi: 10.1002/mds.10252. [DOI] [PubMed] [Google Scholar]
  49. Hyman N., Barnes M., Bhakta B., Cozens A., Bakheit M., Kreczy-Kleedorfer B., Poewe W., Wissel J., Bain P., Glickman S. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000 Jun;68(6):707–712. doi: 10.1136/jnnp.68.6.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Jankovic J. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve. 2001 Nov;24(11):1568–1570. doi: 10.1002/mus.1186. [DOI] [PubMed] [Google Scholar]
  51. Jankovic J., Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987 Apr;37(4):616–623. doi: 10.1212/wnl.37.4.616. [DOI] [PubMed] [Google Scholar]
  52. Jankovic J., Schwartz K., Clemence W., Aswad A., Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996 May;11(3):250–256. doi: 10.1002/mds.870110306. [DOI] [PubMed] [Google Scholar]
  53. Jankovic J., Schwartz K., Donovan D. T. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990 Aug;53(8):633–639. doi: 10.1136/jnnp.53.8.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Jankovic J. Tourette's syndrome. N Engl J Med. 2001 Oct 18;345(16):1184–1192. doi: 10.1056/NEJMra010032. [DOI] [PubMed] [Google Scholar]
  55. Jankovic J., Vuong K. D., Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003 Apr 8;60(7):1186–1188. doi: 10.1212/01.wnl.0000055087.96356.bb. [DOI] [PubMed] [Google Scholar]
  56. Jankovic Joseph. Dystonia: medical therapy and botulinum toxin. Adv Neurol. 2004;94:275–286. [PubMed] [Google Scholar]
  57. Jankovic Joseph. Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004 Mar;19 (Suppl 8):S109–S115. doi: 10.1002/mds.20024. [DOI] [PubMed] [Google Scholar]
  58. Joo J. S., Agachan F., Wolff B., Nogueras J. J., Wexner S. D. Initial North American experience with botulinum toxin type A for treatment of anismus. Dis Colon Rectum. 1996 Oct;39(10):1107–1111. doi: 10.1007/BF02081409. [DOI] [PubMed] [Google Scholar]
  59. Kessler K. R., Skutta M., Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol. 1999 Apr;246(4):265–274. doi: 10.1007/s004150050345. [DOI] [PubMed] [Google Scholar]
  60. Kirazli Y., On A. Y., Kismali B., Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil. 1998 Nov-Dec;77(6):510–515. doi: 10.1097/00002060-199811000-00012. [DOI] [PubMed] [Google Scholar]
  61. Kokoska Mimi S., Amato Jason B., Hollenbeak Christopher S., Glaser Dee Anna. Modifications of eyebrow position with botulinum exotoxin A. Arch Facial Plast Surg. 2002 Oct-Dec;4(4):244–247. doi: 10.1001/archfaci.4.4.244. [DOI] [PubMed] [Google Scholar]
  62. Krauss J. K., Toups E. G., Jankovic J., Grossman R. G. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1997 Nov;63(5):642–648. doi: 10.1136/jnnp.63.5.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Kwak C. H., Hanna P. A., Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol. 2000 Aug;57(8):1190–1193. doi: 10.1001/archneur.57.8.1190. [DOI] [PubMed] [Google Scholar]
  64. Lang Amy M. Botulinum toxin therapy for myofascial pain disorders. Curr Pain Headache Rep. 2002 Oct;6(5):355–360. doi: 10.1007/s11916-002-0076-8. [DOI] [PubMed] [Google Scholar]
  65. Maria G., Destito A., Lacquaniti S., Bentivoglio A. R., Brisinda G., Albanese A. Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet. 1998 Aug 22;352(9128):625–625. doi: 10.1016/S0140-6736(05)79580-5. [DOI] [PubMed] [Google Scholar]
  66. Marras C., Andrews D., Sime E., Lang A. E. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology. 2001 Mar 13;56(5):605–610. doi: 10.1212/wnl.56.5.605. [DOI] [PubMed] [Google Scholar]
  67. Matarasso A., Matarasso S. L., Brandt F. S., Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg. 1999 Feb;103(2):645–655. doi: 10.1097/00006534-199902000-00043. [DOI] [PubMed] [Google Scholar]
  68. Merlo Ilaria Maria, Occhini Antonio, Pacchetti Claudio, Alfonsi Enrico. Not paralysis, but dystonia causes stridor in multiple system atrophy. Neurology. 2002 Feb 26;58(4):649–652. doi: 10.1212/wnl.58.4.649. [DOI] [PubMed] [Google Scholar]
  69. Molloy F. M., Shill H. A., Kaelin-Lang A., Karp B. I. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology. 2002 Mar 12;58(5):805–807. doi: 10.1212/wnl.58.5.805. [DOI] [PubMed] [Google Scholar]
  70. Naumann M. K., Hamm H., Lowe N. J., Botox Hyperhidrosis Clinical Study Group Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol. 2002 Dec;147(6):1218–1226. doi: 10.1046/j.1365-2133.2002.05059.x. [DOI] [PubMed] [Google Scholar]
  71. Naumann M., Jost W. H., Toyka K. V. Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch Neurol. 1999 Aug;56(8):914–916. doi: 10.1001/archneur.56.8.914. [DOI] [PubMed] [Google Scholar]
  72. Nuzzo R. M., Walsh S., Boucherit T., Massood S. Counterparalysis for treatment of paralytic scoliosis with botulinum toxin type A. Am J Orthop (Belle Mead NJ) 1997 Mar;26(3):201–207. [PubMed] [Google Scholar]
  73. Ondo William G., Hunter Christine, Moore Warren. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004 Jan 13;62(1):37–40. doi: 10.1212/01.wnl.0000101713.81253.4c. [DOI] [PubMed] [Google Scholar]
  74. Pasricha P. J., Miskovsky E. P., Kalloo A. N. Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction. Gut. 1994 Sep;35(9):1319–1321. doi: 10.1136/gut.35.9.1319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Pasricha P. J., Ravich W. J., Hendrix T. R., Sostre S., Jones B., Kalloo A. N. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med. 1995 Mar 23;332(12):774–778. doi: 10.1056/NEJM199503233321203. [DOI] [PubMed] [Google Scholar]
  76. Porta M., Gamba M., Bertacchi G., Vaj P. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):538–540. doi: 10.1136/jnnp.70.4.538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Repka M. X., Savino P. J., Reinecke R. D. Treatment of acquired nystagmus with botulinum neurotoxin A. Arch Ophthalmol. 1994 Oct;112(10):1320–1324. doi: 10.1001/archopht.1994.01090220070025. [DOI] [PubMed] [Google Scholar]
  78. Restivo Domenico A., Palmeri Agostino, Marchese-Ragona Rosario. Botulinum toxin for cricopharyngeal dysfunction in Parkinson's disease. N Engl J Med. 2002 Apr 11;346(15):1174–1175. doi: 10.1056/NEJM200204113461517. [DOI] [PubMed] [Google Scholar]
  79. Rivest J., Lees A. J., Marsden C. D. Writer's cramp: treatment with botulinum toxin injections. Mov Disord. 1991;6(1):55–59. doi: 10.1002/mds.870060110. [DOI] [PubMed] [Google Scholar]
  80. Rollnik J. D., Hierner R., Schubert M., Shen Z. L., Johannes S., Tröger M., Wohlfarth K., Berger A. C., Dengler R. Botulinum toxin treatment of cocontractions after birth-related brachial plexus lesions. Neurology. 2000 Jul 12;55(1):112–114. doi: 10.1212/wnl.55.1.112. [DOI] [PubMed] [Google Scholar]
  81. Saadia D., Voustianiouk A., Wang A. K., Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology. 2001 Dec 11;57(11):2095–2099. doi: 10.1212/wnl.57.11.2095. [DOI] [PubMed] [Google Scholar]
  82. Schiano T. D., Parkman H. P., Miller L. S., Dabezies M. A., Cohen S., Fisher R. S. Use of botulinum toxin in the treatment of achalasia. Dig Dis. 1998 Jan-Feb;16(1):14–22. doi: 10.1159/000016845. [DOI] [PubMed] [Google Scholar]
  83. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000 Apr;80(2):717–766. doi: 10.1152/physrev.2000.80.2.717. [DOI] [PubMed] [Google Scholar]
  84. Schmitt W. J., Slowey E., Fravi N., Weber S., Burgunder J. M. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache. 2001 Jul-Aug;41(7):658–664. doi: 10.1046/j.1526-4610.2001.041007658.x. [DOI] [PubMed] [Google Scholar]
  85. Schurch B., Schmid D. M., Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000 Mar 2;342(9):665–665. doi: 10.1056/NEJM200003023420918. [DOI] [PubMed] [Google Scholar]
  86. Scott A. B. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc. 1981;79:734–770. [PMC free article] [PubMed] [Google Scholar]
  87. Sheean Geoffrey. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep. 2002 Dec;6(6):460–469. doi: 10.1007/s11916-002-0065-y. [DOI] [PubMed] [Google Scholar]
  88. Tan E. K., Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000 Feb;131(2):211–216. doi: 10.14219/jada.archive.2000.0149. [DOI] [PubMed] [Google Scholar]
  89. Tintner R., Jankovic J. Focal dystonia: the role of botulinum toxin. Curr Neurol Neurosci Rep. 2001 Jul;1(4):337–345. doi: 10.1007/s11910-001-0087-6. [DOI] [PubMed] [Google Scholar]
  90. Wang A., Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998 Dec;21(12):1740–1747. doi: 10.1002/(sici)1097-4598(199812)21:12<1740::aid-mus17>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  91. Warrick P., Dromey C., Irish J. C., Durkin L., Pakiam A., Lang A. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Laryngoscope. 2000 Aug;110(8):1366–1374. doi: 10.1097/00005537-200008000-00028. [DOI] [PubMed] [Google Scholar]
  92. Whelchel Dorothy D., Brehmer Tonia M., Brooks Paula M., Darragh Neely, Coffield Julie A. Molecular targets of botulinum toxin at the mammalian neuromuscular junction. Mov Disord. 2004 Mar;19 (Suppl 8):S7–S16. doi: 10.1002/mds.20004. [DOI] [PubMed] [Google Scholar]
  93. Wissel J., Masuhr F., Schelosky L., Ebersbach G., Poewe W. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord. 1997 Sep;12(5):722–726. doi: 10.1002/mds.870120516. [DOI] [PubMed] [Google Scholar]
  94. Zermann D. h., Ishigooka M., Schubert J., Schmidt R. A. Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol. 2000 Oct;38(4):393–399. doi: 10.1159/000020314. [DOI] [PubMed] [Google Scholar]
  95. de Paiva A., Meunier F. A., Molgó J., Aoki K. R., Dolly J. O. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3200–3205. doi: 10.1073/pnas.96.6.3200. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES